title: Chemotherapy for small cell lung cancer: induction and reinduction with VOCA.
abstract: Sixty-five patients with small cell lung cancer were treated with VP16, vincristine, cyclophosphamide, and doxorubicin (VOCA) intravenously at three-week intervals. Patients with limited disease received four cycles with responders receiving radiation to the primary site and prophylactic cranial irradiation. Patients with extensive disease received chemotherapy only. Of 59 patients evaluable for chemotherapy response, eight (14%) achieved complete remission and 30 (51%) partial remission. Major side-effects included myelosuppression, alopecia, nausea, and vomiting. Reinduction with VOCA at relapse yielded objective or subjective response in four of seven patients. This regimen is active in small cell lung cancer and was well tolerated by patients. Reinduction of response was possible in a small number of patients retreated and may provide useful palliation for those who relapse when treatment is discontinued.
authors.affiliation: Ludwig Institute for Cancer Research, University of Sydney.
authors.forename: R
authors.initials: R
authors.lastname: Stuart-Harris
authors.forename: D
authors.initials: D
authors.lastname: Raghavan
authors.forename: R M
authors.initials: RM
authors.lastname: Fox
authors.forename: G
authors.initials: G
authors.lastname: Peretz
authors.forename: C
authors.initials: C
authors.lastname: Crombie
authors.forename: N
authors.initials: N
authors.lastname: Teriana
authors.forename: I
authors.initials: I
authors.lastname: Young
authors.forename: P
authors.initials: P
authors.lastname: Bye
authors.forename: K
authors.initials: K
authors.lastname: Tiver
authors.forename: D
authors.initials: D
authors.lastname: Green
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000532:radiotherapy; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000008:administration & dosage / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011034:Podophyllotoxin